USANA HEALTH SCIENCES INC (USNA) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Latest close $13.22 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Pzena Investment Management — 1 tracked fund hold USNA. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
Merck & Co., Inc. (MRK) · LINDE PLC (LIN) · ELI LILLY & Co (LLY) · PROCTER & GAMBLE Co (PG) · PFIZER INC (PFE) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Pzena Investment Management | 0.08% | 1,205,587 | ADDED (+8.7%) Q3 filed Oct 30 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -37.5% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 138 of 8,857 filers |
| Long-only filers among them | 138 |
| Change vs 2026 Q1 | +6 net · 135 entered · 129 exited |
| Shares reported, all filers | 11,386,513 |
| Reported value, all filers | $239.9M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Medicinal Chemicals & Botanical Products (SIC 2833) |
| Revenue · FY2026 | $925.3M |
| Net income · FY2026 | $10.8M |
| Total assets · FY2026 | $742.9M |
| Shares outstanding | 18,476,534 |
| Market cap (at latest close) | $244.3M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 11, 2026.
| Shares short · Oct 15, 2026 | 779,033 |
| Share of shares outstanding | 4.22% |
| Days to cover | 4.43 |
Shares short at recent settlements — Jul 31, 2026: 690K · Aug 14, 2026: 756K · Aug 31, 2026: 646K · Sep 15, 2026: 755K · Sep 30, 2026: 772K · Oct 15, 2026: 779K.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 11, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 11, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | BRENT LOWELL NEIDIG | Officer | 5,002 | $97.3K | Jun 16, 2026 | SEC filing |
| Jun 15, 2026 | BRENT LOWELL NEIDIG | Officer | 909 | $18.2K | Jun 15, 2026 | SEC filing |
| Jun 8, 2026 | PAUL A JONES | Officer | 5,561 | $102.9K | Jun 8, 2026 | SEC filing |
| May 28, 2026 | PAUL A JONES | Officer | 6,813 | $129.1K | May 28, 2026 | SEC filing |
| May 27, 2026 | GARY DOUGLAS HEKKING | Officer | 5,360 | $100.5K | May 27, 2026 | SEC filing |
| May 7, 2026 | JOSHUA FOUKAS | Officer | 3,791 | $75.1K | May 7, 2026 | SEC filing |
| Mar 3, 2026 | PETER G BENEDICT | Officer | 4,553 | $88.3K | Mar 3, 2026 | SEC filing |
| Feb 20, 2026 | JOSHUA FOUKAS | Officer | 4,461 | $95.2K | Feb 20, 2026 | SEC filing |
| Dec 10, 2025 | PETER G BENEDICT | Officer | 2,673 | $56.0K | Dec 10, 2025 | SEC filing |
| Aug 28, 2025 | PAUL A JONES | Officer | 5,169 | $165.4K | Aug 28, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Mar 30, 2026 | SCHEDULE 13D/A | -22.3% (close Mar 31, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Mar 31, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Renaissance Technologies LLC | SC 13G/A | 958,520 | 5.2% | Jun 30, 2026 | SEC filing |
| Mar 30, 2026 | Gull Global Limited | SC 13D/A | 7,408,345 | 40.1% | Mar 26, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Jan 21, 2026 | BlackRock, Inc. | SC 13G/A | 799,296 | 4.4% | Dec 31, 2025 | SEC filing |
| Jan 21, 2026 | Dimensional Fund Advisors LP | SC 13G/A | 848,452 | 4.6% | Dec 31, 2025 | SEC filing |
| Oct 14, 2025 | PZENA INVESTMENT MANAGEMENT LLC | SC 13G/A | 1,212,588 | 6.6% | Sep 30, 2025 | SEC filing |
| Oct 9, 2025 | Dimensional Fund Advisors LP | SC 13G | 915,049 | 5.0% | Sep 30, 2025 | SEC filing |
| Jul 29, 2025 | The Vanguard Group | SC 13G/A | 1,011,783 | 5.4% | Jun 30, 2025 | SEC filing |
| Apr 30, 2025 | The Vanguard Group | SC 13G/A | 1,373,908 | 7.3% | Mar 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Medicinal Chemicals & Botanical Products (SIC 2833). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 42 Lobbying Disclosure Act filings named this company as client, 2017–2026; most common issues: Labor Issues/Antitrust/Workplace (29), Telecommunications (23), Consumer Issues/Safety/Products (13).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Graham — Sound finances and a long run of profits
· Piotroski — Financial health improved over the past year
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Earnings Stability — Small earnings swings and almost no loss years
Key figures
· Graham — Current ratio: 2.24 · Straight profitable years: 14 · Debt ratio: 0.29 · Latest net income: $10.8M
· Piotroski — F-score: 7 · Return on assets: 1.5% · Operating cash flow: $22.3M
· Gross Profitability (Novy-Marx) — Gross profit / assets: 97.5% · Gross margin: 78.3%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.55 · Operating cash flow: $22.3M · Net income: $10.8M
· Earnings Stability — Earnings variation (CV): 0.44 · Loss years (of 10): 0 · Latest net income: $10.8M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Share count tripled (3x) | 1 | 0.0% | -18.4% | -8.2% | -10.2% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold USNA — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · LINDE PLC (LIN) · ELI LILLY & Co (LLY) · PROCTER & GAMBLE Co (PG) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · COLGATE PALMOLIVE CO (CL).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 3, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 5, 2026 | 1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 4, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on USNA
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.